Hepatitis C pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 52: Line 52:
{{Reflist|2}}
{{Reflist|2}}


[[Category:Hepatitis|C]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
[[Category:Disease]]
[[Category:FinalQCRequired]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}

Revision as of 13:13, 27 October 2016

Hepatitis Main Page

Hepatitis C

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology & Demographics

Risk Factors

Screening

Differentiating Hepatitis C from other Diseases

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Hepatitis C pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis C pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis C pathophysiology

CDC on Hepatitis C pathophysiology

Hepatitis C pathophysiology in the news

Blogs on Hepatitis C pathophysiology

Directions to Hospitals Treating Hepatitis C

Risk calculators and risk factors for Hepatitis C pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Yazan Daaboul, Serge Korjian, Seyedmahdi Pahlavani, M.D. [2]

Overview

In isolated acute HCV infection, the host immune system stimulates the secretion of interferon alpha and the activation of natural killer cells, which is followed by the activation of the adaptive immune system. Chronic HCV is characterized by the impairment of these mechanisms. Eventually, chronic HCV infection leads to local inflammation and fibrogenesis, which cause hepatic injury and cirrhosis. Hepatocellular carcinoma, a known complication of chronic HCV infection, arises in cases of cirrhosis; the role of oncogenic proteins of HCV in the pathogenesis of hepatocellular carcinoma has yet to be elucidated.

Transmission

The transmission of HCV can be defined as percutaneous, sexual, healthcare-associated, or maternal-infant in nature.

Percutaneous Transmission

  • Blood and blood components transfusion
    • More than 90% of seronegative recipients who are transfused with blood from HCV-antibody positive donors will acquire infection.[1]
  • Contaminated shared needles among intravenous drug users
    • Before 1992, at least two-thirds of new HCV infections in the United States were associated with illicit drug use; the number has since decreased significantly.[2]
  • Chronic hemodialysis
    • The frequency of anti-HCV in patients on hemodialysis ranges from less than 10% in the United States to 55% to 85% in Jordan, Saudi Arabia, and Iran.[3]

Sexual Transmission

  • HCV RNA has been detected in semen and saliva.[4] People with multiple sexual partners and commercial sex workers have a high HCV prevalence.[5]

Health care Associated

  • Nosocomial transmission has been observed under several different conditions (e.g. needle stick, organ transplant, during surgery); now, however, because of infection control protocols, nosocomial transmission of HCV is rare except in cases of breach of protocols.[6][7]

Maternal Infant Transmission

  • Perinatal transmission frequency ranges from 0% to 4% in larger studies.[8][9]

HCV Clearance and Persistence

Acute viral infection and HCV replication triggers the activation of host immune responses, first by secretion of type I interferon alpha (IFN-alpha) and activation of natural killer (NK) cells. Nonetheless, secretion of endogenous IFN does not seem to effectively inhibit HCV replication.[10][11][12]

HCV proteins play a crucial role in inhibiting IFN-alpha effectors, such as IFN regulatory factor-3 (IRF-3), double stranded RNA-dependent protein kinase (PKR), and the JAK-STAT signaling pathway.[13][14][15] More importantly, chronic carriage of HCV is associated with impaired activation of NK cells despite IFN-alpha secretion. It is believed that the cross-linking of CD81 and the envelope protein E2 of the virus is a key mechanism by which NK cells are inactivated and INF-gamma is not produced by these cells.[16]

The activation of IFN-gamma is a prerequisite for the appropriate clearance of HCV. When activation occurs normally, antibodies start to form 7-31 weeks later.[17][18][19][20] While most epitopes for antibodies have not been discovered yet, hypervariable region 1 (HVR1) of the E2 envelope glycoprotein was found to be a target for anti-HVR1 antibodies. Antibodies play a role in clearing the virus from the host. It is currently unknown whether "escape" mechanisms are present in HCV that favor persistent HCV infection despite an adequate antibody response.[17][18][19][20]

Similarly, the activation of the CD4+ and CD8+ T-cell response is required for viral clearance. This cellular response allows for the development of long-term immunity against HCV.[21] Studies also proved that delayed or inadequate activation of T-cell response is associated with persistence of infection. It is not known why T-cell response may fail in response to acute infection, but it is hypothesized that persistence might be related to viral inhibition of T-cell maturation, defective dendritic cells, and/or failure of interleukin (IL) 12 activation.[21][22][23][24][25][26]

Liver Injury and Cirrhosis, and Hepatocellular Carcinoma

HCV is directly associated with hepatic steatosis, which is fat accumulation in the liver. It seems that core proteins may play a role in regulating lipid accumulation in hepatocytes, contributing to steatosis. However, steatosis is not observed in all genotypes of HCV infection; it is classically described in genotype 3, which perhaps is the only genotype that has a direct role in the development of steatosis irrespective of alcohol consumption or metabolic elements. Apart from steatosis, HCV per se has not been shown to have damaging effects on hepatocytes. The viral burden also does not seem to be directly related to the extent of liver injury.[27][28][29][30][31][32][33]

In chronic hepatitis C infections, the local immune response leads to portal lymphoid infiltration and chronic inflammation, which give way to bridging necrosis and degenerative lobular lesions.[16] Hepatic injury is directly associated with the degree of Th1 cytokine expression. The adaptive immune system, namely the cytotoxic T-cell response, injures infected cells as well as bystander cells. Nonetheless, it has not been confirmed whether the number of cytotoxic T cells is associated with the extent of liver injury.

Chronic inflammation ultimately leads to fibrogenesis due to deposition extracellular matrix elements in hepatic parenchyma. It is unknown whether viral components are directly responsible in the particular mechanism of hepatic cirrhosis in chronic HCV infection; although cirrhosis is definitely worsened in HCV patients who are also exposed to other risk factors, such as alcohol, obesity, and HIV.[16]

Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) occurs following chronic HCV infection complicated by liver cirrhosis. The precise role of HCV components in the development of HCC is poorly understood. Pinpointing which viral protein is directly related to carcinogenesis has been difficult, but studies have shown that NS3, NS4B, and NS5A all have oncogenic properties.[34][35][36][37][38]

Histology

Click on the arrow to view the pathologic findings in viral hepatitis: {{#ev:youtube|_hXvbpSxFZw}}

References

  1. ↑ Vrielink H, van der Poel CL, Reesink HW, Zaaijer HL, Scholten E, Kremer LC, Cuypers HT, Lelie PN, van Oers MH (1995). "Look-back study of infectivity of anti-HCV ELISA-positive blood components". Lancet. 345 (8942): 95–6. PMID 7815889.
  2. ↑ Alter MJ (1997). "Epidemiology of hepatitis C". Hepatology. 26 (3 Suppl 1): 62S–65S. doi:10.1002/hep.510260711. PMID 9305666.
  3. ↑ Jadoul M, Barril G (2012). "Hepatitis C in hemodialysis: epidemiology and prevention of hepatitis C virus transmission". Contrib Nephrol. 176: 35–41. doi:10.1159/000333761. PMID 22310779.
  4. ↑ Liou TC, Chang TT, Young KC, Lin XZ, Lin CY, Wu HL (1992). "Detection of HCV RNA in saliva, urine, seminal fluid, and ascites". J. Med. Virol. 37 (3): 197–202. PMID 1331308.
  5. ↑ van Doornum GJ, Hooykaas C, Cuypers MT, van der Linden MM, Coutinho RA (1991). "Prevalence of hepatitis C virus infections among heterosexuals with multiple partners". J. Med. Virol. 35 (1): 22–7. PMID 1940879.
  6. ↑ Martínez-Bauer E, Forns X, Armelles M, Planas R, Solà R, Vergara M, Fàbregas S, Vega R, Salmerón J, Diago M, Sánchez-Tapias JM, Bruguera M (2008). "Hospital admission is a relevant source of hepatitis C virus acquisition in Spain". J. Hepatol. 48 (1): 20–7. doi:10.1016/j.jhep.2007.07.031. PMID 17998149.
  7. ↑ Alter MJ (2008). "Healthcare should not be a vehicle for transmission of hepatitis C virus". J. Hepatol. 48 (1): 2–4. doi:10.1016/j.jhep.2007.10.007. PMID 18023493.
  8. ↑ Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C, Kako M, Ujiie N, Endo C, Matsui A (1994). "Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group". N. Engl. J. Med. 330 (11): 744–50. doi:10.1056/NEJM199403173301103. PMID 8107740.
  9. ↑ Zanetti AR, Tanzi E, Paccagnini S, Principi N, Pizzocolo G, Caccamo ML, D'Amico E, Cambiè G, Vecchi L (1995). "Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission". Lancet. 345 (8945): 289–91. PMID 7530793.
  10. ↑ Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV (2001). "Determinants of viral clearance and persistence during acute hepatitis C virus infection". J Exp Med. 194 (10): 1395–406. PMC 2193681. PMID 11714747.
  11. ↑ Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C; et al. (2002). "Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease". Proc Natl Acad Sci U S A. 99 (24): 15661–8. doi:10.1073/pnas.202608299. PMC 137773. PMID 12441397.
  12. ↑ Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R; et al. (2002). "Genomic analysis of the host response to hepatitis C virus infection". Proc Natl Acad Sci U S A. 99 (24): 15669–74. doi:10.1073/pnas.202608199. PMC 137774. PMID 12441396.
  13. ↑ Katze MG, He Y, Gale M (2002). "Viruses and interferon: a fight for supremacy". Nat Rev Immunol. 2 (9): 675–87. doi:10.1038/nri888. PMID 12209136.
  14. ↑ Foy E, Li K, Wang C, Sumpter R, Ikeda M, Lemon SM; et al. (2003). "Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease". Science. 300 (5622): 1145–8. doi:10.1126/science.1082604. PMID 12702807.
  15. ↑ Blindenbacher A, Duong FH, Hunziker L, Stutvoet ST, Wang X, Terracciano L; et al. (2003). "Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice". Gastroenterology. 124 (5): 1465–75. PMID 12730885.
  16. ↑ 16.0 16.1 16.2 Pawlotsky JM (2004). "Pathophysiology of hepatitis C virus infection and related liver disease". Trends Microbiol. 12 (2): 96–102. doi:10.1016/j.tim.2003.12.005. PMID 15036326.
  17. ↑ 17.0 17.1 Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R; et al. (1994). "Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization". Proc Natl Acad Sci U S A. 91 (16): 7792–6. PMC 44488. PMID 7519785.
  18. ↑ 18.0 18.1 Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, Purcell RH; et al. (1996). "A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures". Virology. 223 (2): 409–12. doi:10.1006/viro.1996.0497. PMID 8806581.
  19. ↑ 19.0 19.1 Bartosch B, Dubuisson J, Cosset FL (2003). "Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes". J Exp Med. 197 (5): 633–42. PMC 2193821. PMID 12615904.
  20. ↑ 20.0 20.1 Puntoriero G, Meola A, Lahm A, Zucchelli S, Ercole BB, Tafi R; et al. (1998). "Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants". EMBO J. 17 (13): 3521–33. doi:10.1093/emboj/17.13.3521. PMC 1170689. PMID 9649423.
  21. ↑ 21.0 21.1 Bertoletti A, Ferrari C (2003). "Kinetics of the immune response during HBV and HCV infection". Hepatology. 38 (1): 4–13. doi:10.1053/jhep.2003.50310. PMID 12829979.
  22. ↑ Bain C, Fatmi A, Zoulim F, Zarski JP, Trépo C, Inchauspé G (2001). "Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection". Gastroenterology. 120 (2): 512–24. PMID 11159892.
  23. ↑ Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH; et al. (2002). "Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection". J Immunol. 169 (6): 3447–58. PMID 12218168.
  24. ↑ Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P; et al. (2000). "Analysis of successful immune responses in persons infected with hepatitis C virus". J Exp Med. 191 (9): 1499–512. PMC 2213430. PMID 10790425.
  25. ↑ Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L; et al. (2002). "Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections". Nat Med. 8 (4): 379–85. doi:10.1038/nm0402-379. PMID 11927944.
  26. ↑ Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, Hahn YS (2000). "Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation". J Clin Invest. 106 (10): 1239–49. doi:10.1172/JCI10323. PMC 381434. PMID 11086025.
  27. ↑ Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S; et al. (2003). "Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C." Hepatology. 38 (1): 75–85. doi:10.1053/jhep.2003.50267. PMID 12829989.
  28. ↑ Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y; et al. (1997). "Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets". Proc Natl Acad Sci U S A. 94 (4): 1200–5. PMC 19768. PMID 9037030.
  29. ↑ Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G; et al. (2000). "Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3". J Hepatol. 33 (1): 106–15. PMID 10905593.
  30. ↑ Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R (2001). "Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C." J Hepatol. 34 (3): 428–34. PMID 11322205.
  31. ↑ Castéra L, Hézode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM; et al. (2003). "Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies". Gut. 52 (2): 288–92. PMC 1774979. PMID 12524415.
  32. ↑ Sulkowski MS, Thomas DL (2003). "Hepatitis C in the HIV-Infected Person". Ann Intern Med. 138 (3): 197–207. PMID 12558359.
  33. ↑ Pol S, Vallet-Pichard A, Fontaine H, Lebray P (2002). "HCV infection and hemodialysis". Semin Nephrol. 22 (4): 331–9. PMID 12118398.
  34. ↑ National Institutes of Health (2002). "National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002". Hepatology. 36 (5 Suppl 1): S3–20. doi:10.1053/jhep.2002.37117. PMID 12407572.
  35. ↑ Ray RB, Lagging LM, Meyer K, Ray R (1996). "Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype". J Virol. 70 (7): 4438–43. PMC 190377. PMID 8676467.
  36. ↑ Sakamuro D, Furukawa T, Takegami T (1995). "Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells". J Virol. 69 (6): 3893–6. PMC 189112. PMID 7745741.
  37. ↑ Park JS, Yang JM, Min MK (2000). "Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene". Biochem Biophys Res Commun. 267 (2): 581–7. doi:10.1006/bbrc.1999.1999. PMID 10631105.
  38. ↑ Ghosh AK, Steele R, Meyer K, Ray R, Ray RB (1999). "Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth". J Gen Virol. 80 ( Pt 5): 1179–83. PMID 10355764.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Hepatitis_C_pathophysiology&oldid=1264134"
Cookies help us deliver our services. By using our services, you agree to our use of cookies.

Navigation menu